Pre-Test Understanding, Evaluating, and Managing irAEs Associated with CAR T-Cell and BsAb Therapy in Multiple Myeloma Pre-Test Which of the following targets both CD3 T-cell receptors and the GPRC5D MM receptor and has been associated with CRS and ICANS? Elranatamab Isatuximab Teclistamab Talquetamab Unsure CRS and ICANS were seen in ___, respectively, of patients treated with cilta-cel in the CARTITUDE-1 trial. ~20% and ~60% ~40% and ~80% ~60% and ~40% ~80% and ~20% Unsure All of the following may be considered as a therapeutic approach to CAR T- and BsAb-associated CRS except? CD-20 blocade with rituximab IL-6 inhibition with siltuxumab IL-6 inhibition with tocilizumab IL-1 inhibition with anakinra Unsure How confident are you now in your ability to incorporate and implement a multidisciplinary team (MDT) approach to improve MM patient outcomes and quality of life? Very confident Confident Somewhat confident Not very confident Not at all confident
